Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer

• Published in: Medical oncology (Northwood, London, England) London, England), 2010-09, Vol.27 (3), p.571-577
• Main Authors: Al-Tweigeri, Taher A., Ajarim, Dahish S., Alsayed, Adher A., Rahal, Mohamed M., Alshabanah, Mohamed O., Tulbah, Asma M., Al-Malik, Osama A., Fatani, Doha M., El-Husseiny, Gamal A., Elkum, Naser B., Ezzat, Adnan A.
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Carcinoma - drug therapy; Carcinoma - pathology; Cisplatin - administration & dosage; Cisplatin - adverse effects; Combined Modality Therapy; Disease-Free Survival; Doxorubicin - administration & dosage; Estrogens; Female; Genes, erbB-2; Hematology; Humans; Internal Medicine; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent - drug therapy; Neoplasms, Hormone-Dependent - pathology; Oncology; Original Paper; Pathology; Progesterone; Prospective Studies; Radiotherapy, Adjuvant; Tamoxifen - administration & dosage; Taxoids - administration & dosage; Taxoids - adverse effects; Treatment Outcome; Young Adult
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-009-9251-7

The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC). For this evaluation, 59 patients with LABC (T2–T4, N0–N2, M0) received three cycles of doxorubicin, followed by three cycles of cisplatin/docetaxel and followed by definitive surgery and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast and axilla. Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4–10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%. Clinical complete response was seen in 44%, and clinical partial response was seen in 56%. Breast conserving surgery was performed in 44%, and MRM in 56%. pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%. Overall at follow-up of 60 months, the disease-free (DFS) and overall survival (OS) were 70 and 82%, respectively. The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive. Sequential combination of doxorubicin followed by docetaxel/cisplatin is a safe, feasible, and active combination, which offers the possibility of conservative surgery and is associated with high clinical and pathologic response rates, with promising and encouraging survival outcomes.